Type 2 diabetes is manifested by impaired insulin secretion in pancreatic beta cells, increased glucagon secretion in alpha cells, and generally has a history of insulin resistance. The treatment of glucose metabolism disorder and the resulting hyperglycemia constitute an important part of the treatment of type 2 diabetes. Glycemic targets can be targeted with A1C <7% to reduce the risk of micro and macrovascular complications in eligible patients, and A1C <6.5% to reduce the risk of diabetic chronic renal failure and retinopathy in those with low risk of hypoglycemia. We can consider the treatment of hyperglycemia in two components; lifestyle changes and glucose-lowering agent therapy.
Primary Language | English |
---|---|
Subjects | Internal Diseases |
Journal Section | Editorial |
Authors | |
Publication Date | January 29, 2021 |
Submission Date | October 20, 2020 |
Acceptance Date | November 4, 2020 |
Published in Issue | Year 2021 |